The bevacizumab biosimilars market, valued at USD 1.86 billion in 2024, is projected to more than double by 2032, reaching USD 3.70 billion, according to new market insights. This growth is expected to be achieved at a compound annual growth rate (CAGR) of 9.01% during the forecast period of 2025–2032, fueled by increasing cancer prevalence and global emphasis on cost-effective cancer treatment.
Rising Cancer Burden to Drive Demand
Cancer continues to pose a significant public health threat, with the World Health Organization (WHO) projecting a 77% increase in global cancer cases by 2050. With colorectal, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and other malignancies on the rise, there is an urgent need for accessible and affordable therapeutic alternatives.
Discover Market Shifts: Secure Your Sample Report Now! https://www.snsinsider.com/sample-request/7308
Bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), is widely used to treat various cancers. However, the high cost of the originator biologic product has driven the demand for biosimilars, which are 15%–30% more affordable, according to FDA data. This affordability, without compromising clinical efficacy, makes bevacizumab biosimilars an attractive choice for healthcare providers and payers globally.
Market Dynamics
Drivers:
- High prevalence of cancer: Rising cancer incidences, particularly colorectal, lung, and renal cancers, are boosting demand for bevacizumab-based therapies.
- Cost efficiency: With biosimilars offering up to 30% cost savings compared to reference biologics, healthcare systems globally are embracing these alternatives.
- Patent expirations: The expiration of Avastin's patent has opened avenues for biosimilar manufacturers to capture significant market share.
- Regulatory support: Increasing approvals by regulatory bodies like the FDA, EMA, and PMDA are facilitating faster market access for biosimilars.
Restraints:
- Complex manufacturing process: Biologics and their biosimilars require sophisticated technology and strict quality controls, which can increase development costs.
- Physician skepticism: A fraction of healthcare professionals still hesitate to switch from branded biologics to biosimilars due to efficacy or immunogenicity concerns.
- Patent litigations: Legal disputes between originator and biosimilar developers can delay product launches in certain markets.
Opportunities:
- Emerging markets: Countries in Asia-Pacific, Latin America, and the Middle East present lucrative growth potential due to increasing healthcare investments and cancer diagnosis rates.
- Collaborations and partnerships: Strategic alliances among pharma companies, CROs, and research institutions are accelerating biosimilar R&D and market penetration.
Challenges:
- Market access and reimbursement: Navigating the regulatory and reimbursement landscape across regions remains a challenge for new market entrants.
- Supply chain constraints: Ensuring consistent supply and maintaining cold chain logistics are critical, especially in emerging economies.
Key Takeaways
- The global bevacizumab biosimilars market is expected to grow at a CAGR of 9.01% from 2025 to 2032.
- Increasing cancer burden and biosimilar affordability are key growth drivers.
- Avastin, Mvasi, Zirabev, and Aybintio are among the major products in the market.
- Colorectal cancer and non-small cell lung cancer dominate application segments.
- Hospital pharmacies hold the largest distribution channel share, with online pharmacies gaining traction.
- North America, Europe, and Asia-Pacific are the most significant regional contributors.
Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report! https://www.snsinsider.com/reports/bevacizumab-biosimilars-market-7308
Regional Analysis
North America
The North American region, particularly the United States, continues to lead in biosimilar adoption, supported by a favorable reimbursement environment, strong healthcare infrastructure, and early regulatory approvals. The presence of major players like Amgen, Pfizer, and Mylan further bolsters market strength in the region.
Europe
Europe remains at the forefront of biosimilar usage, driven by robust regulatory frameworks from the European Medicines Agency (EMA) and cost-containment strategies by national health services. Countries like Germany, the UK, and France have shown high uptake of bevacizumab biosimilars.
Asia Pacific
The Asia-Pacific region is anticipated to witness the fastest growth due to increasing cancer prevalence, expanding healthcare access, and government initiatives to promote biosimilar adoption in countries such as China, India, and South Korea.
Middle East & Africa
While still in the nascent stage, MEA offers untapped growth potential, especially with the rising incidence of cancer and improving diagnostic capabilities. However, market access challenges and regulatory inconsistencies could limit rapid expansion.
Latin America
Countries such as Brazil, Argentina, and Mexico are gradually recognizing the benefits of biosimilars. Although economic constraints persist, the push toward universal healthcare is expected to support future growth.
Key Market Players
The bevacizumab biosimilars market is characterized by intense competition and strong innovation pipelines. Leading bevacizumab biosimilars companies operating in the market comprise Amgen, AryoGen, Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio, and TOT Biopharm.
These companies are actively engaged in clinical trials, regulatory submissions, and partnerships to expand their global footprint and ensure affordable oncology solutions reach patients in need.
Market Segmentation
By Product
- Avastin (reference biologic)
- Mvasi
- Zirabev
- Aybintio
- Others
By Application
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Conclusion
The global bevacizumab biosimilars market is poised for remarkable growth over the coming decade, driven by a convergence of factors—rising cancer rates, healthcare cost pressures, and advancements in biopharmaceutical innovation. As governments and healthcare providers strive to deliver value-based care, bevacizumab biosimilars will play an increasingly central role in broadening patient access to life-saving therapies without compromising on quality or efficacy.
For stakeholders across the pharmaceutical value chain, the opportunity to invest in or collaborate within this rapidly evolving space has never been more promising.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Comments
0 comment